Evidence-based decision-making on medical technologies in China, Japan, and Singapore

Value in Health

Volumn 12, Issue SUPPL. 3, 2009, Pages

  Liu, Gordon G ^a   Fukuda, Takashi ^b   Lee, Chien Earn ^c   Chen, Vivian ^d   Zheng, Qiang ^e   Kamae, Isao ^f  

^a Peking University   (China)

^b UNIVERSITY OF TOKYO   (Japan)

^c MINISTRY OF HEALTH   (Singapore)

^d RandD Based Pharmaceutical Association of China   (China)

^e PEKING UNIVERSITY   (China)

^f KEIO UNIVERSITY   (Japan)

Author keywords

Cost effectiveness; Drug regulation; Health reform; Medical technology; Pricing; Reimbursement

Indexed keywords

ESSENTIAL DRUG; NEW DRUG; NON PRESCRIPTION DRUG;

CHINA; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG MARKETING; EVIDENCE BASED PRACTICE; GOVERNMENT REGULATION; HEALTH CARE POLICY; HUMAN; JAPAN; MEDICAL TECHNOLOGY; MONEY; PRIORITY JOURNAL; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; SAFETY; SINGAPORE;

EID: 72149132818     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2009.00621.x     Document Type: Review

References (11)

1. The State Council, China. Directives on Furthering Health Reform (in Chinese). 2009.
2. Liu GG, Zhao Z. Urban health insurance reform in China and the impact on out-of-pocket payment. Int J Health Plann Manage 2006 21 : 1 19.
3. Ministry of Health, Singapore. Healthcare system: overview. Available from: http://www.moh.gov.sg/mohcorp/hcsystem.aspx?id=102 [Accessed August 7, 2009 GG, Zhao Z, Cai R, et al. Equity in health care access: assessing the urban health care reform in China. Soc Sci Med 2002 55 : 1779 1794.
4. Lin WC, Liu GG, Chen G. Urban resident basic medical insurance: a landmark reform toward universal coverage in China. Health Econ 2009 18 (Suppl. S83 96.
5. Ministry of Health, Singapore. Healthcare financing: overview. Available from: http://www.moh.gov.sg/mohcorp/hcfinancing.aspx?id=104 [Accessed August 7, 2009 February 13, 2009 February 13, 2009 D. Need for A Contract Manufacturing System in China. Health News (in Chinese), July 29, 2008.
6. Mao DL. Clinical Trials in China: Speed vs. Quality (in Chinese) China Prescription Drugs 2008 11 : 28.
7. Sakamaki H, Hiromori N, Aburaya Y, et al. A survey of pharmacoeconomic data in applications for NHI new drug price listing in Japan. Jpn J Pharmacoepidemiol 2001 6 : 83 100.
8. Ikeda S, Onozuka S. Pharmacoeconomic evaluations for price negotiations in Japan. J Health Care Soc 2005 14 : 145 158.
9. Pwee KH. HTA in Singapore. Int J Technol Assess Health Care 2009 25 (Suppl. 1 234 240.
10. The R&D Based Pharmaceutical Association of China. Pricing Study of Pharmaceutical Market in China, RDPAC Internal Study. 2008.
11. Lee HY, Wong WY. First year results of the medisave for Chronic Disease Management Programme (CDMP). Available from: http://www.moh.gov.sg/mohcorp/ publicationsinfopapers.aspx?id=18650 [Accessed August 7, 2009 HY, Mervani NI, Moolayil A. Medisave for Chronic Disease Management Programme (CDMP) - the second year. Available from: http://www.moh.gov.sg/mohcorp/ publicationsinfopapers.aspx?id=22238 [Accessed August 7, 2009 ].